General Proximity
General Proximity is a San Francisco preclinical biotech that built OmniTAC™, a mechanism-agnostic induced-proximity discovery engine scanning the effector proteome to generate therapeutics for previously undruggable targets, partnering with large pharmaceutical companies (e.g., Daiichi Sankyo) across oncology, cardiometabolic, neurodegeneration, and longevity.
- Company typePrivate
- Founded2019
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What General Proximity does
General Proximity is a San Francisco-based preclinical biotechnology company founded in 2019 by Armand B. Cognetta III, PhD, that has built OmniTAC™, a proprietary mechanism-agnostic proximity discovery engine. The platform systematically scans the "effectome" — the universe of effector proteins (chaperones, adaptors, trafficking proteins, post-translational modification readers/writers/erasers) capable of modulating other proteins — to identify induced-proximity events that can yield therapeutics against targets historically considered undruggable by conventional small molecules, PROTACs, or molecular glues. Outputs include bifunctional and heterobifunctional molecules spanning oncology, cardiometabolic disease, neurodegeneration, and longevity programs.
The company is leveraging a differentiated scientific lineage (proximity pioneers Craig Crews and Amit Choudhary labs), an in-house ultra-high-throughput proximity screening engine, cryo-EM/SAXS/ITC/NMR structural biology, and CRISPRi functional genomics supported by AWS HealthOmics HPC infrastructure. General Proximity does not sell commercial products; its business model is multi-target pharma discovery collaborations (e.g., the November 2025 Daiichi Sankyo multi-target oncology deal) plus non-dilutive grants (ARPA-H $3M, NIH NCI SBIR $400K) and venture financing. Customer segments are large pharmaceutical R&D organizations seeking first-in-class modalities for undruggable targets, with a secondary Asia-market entry pathway opened via Daewoong Pharmaceutical.
General Proximity firmographics
Firmographics- Name
- General Proximity
- Legal name
- General Proximity
- Website
- https://generalproximity.bio
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- General Proximity is a San Francisco preclinical biotech that built OmniTAC™, a mechanism-agnostic induced-proximity discovery engine scanning the effector proteome to generate therapeutics for previously undruggable targets, partnering with large pharmaceutical companies (e.g., Daiichi Sankyo) across oncology, cardiometabolic, neurodegeneration, and longevity.
- Ownership category
- akta.pro rank
General Proximity industry classification
Industry- Product category
- Biotechnology Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)
- akta.pro secondary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where General Proximity is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
General Proximity business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain
Revenue model
- Pharma discovery & collaboration agreements: Multi-target discovery collaborations with large pharma (e.g., Daiichi Sankyo multi-target oncology collaboration announced Nov 12, 2025) under which GP applies OmniTAC™ to identify effector-target pairs. Typical biotech discovery-deal structure with upfront payments, R&D funding, milestone payments, and potential royalties on future products.
- Strategic equity investment from pharma/VC partners: Direct equity investment from FreeMind Investments (FreeMind Group + Daewoong Pharmaceutical co-founded VC fund), with intent to explore future strategic collaboration — Daewoong's interest is in General Proximity's induced-proximity platform for potential Asia-market collaboration.
- Non-dilutive grant funding: Non-dilutive grants including ARPA-H Sprint for Women's Health award ($3M) and NIH NCI SBIR Phase I grant ($400K for Triple Negative Breast Cancer), plus AWS credits and technical support via ARPA-H Investor Catalyst Hub.
- Venture capital / private equity financing: Pre-seed (Y Combinator, Jim Dahl/Rock Creek) and seed financing ($8M led by Felicis, with age1, Modi Ventures, Wilson Sonsini, plus angels); de-stealth $16M total raise; subsequent round bringing total funding to over $20M.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Discovery collaboration deals — terms not publicly disclosed |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels6 records
General Proximity product offering
Product offeringCore offering
General Proximity develops the proprietary OmniTAC™ platform, a mechanism-agnostic proximity discovery engine that scans the "effectome" to identify effector proteins capable of modulating disease-driving targets. The platform generates preclinical induced-proximity therapeutic candidates (heterobifunctional/bifunctional small molecules) against previously undruggable targets across oncology, cardiometabolic disease, neurodegeneration, and longevity, delivered to large-pharma partners via multi-target discovery collaborations and licensing deals.
Product overview
General Proximity offers a single unified drug-discovery platform — the proprietary OmniTAC™ platform — that functions as a mechanism-agnostic proximity discovery engine. The platform scans the 'effectome' (effector proteins capable of modulating other proteins) to uncover therapeutically useful proximity events and generates novel induced-proximity medicines (heterobifunctional / bifunctional molecules) for previously undruggable targets. The platform generates multiple preclinical pipeline programs: OmniTAC™ Oncology Programs (including a Daiichi Sankyo multi-target collaboration and an ARPA-H-funded women's cancer program), a Cardiometabolic Disease Program, a Neurodegeneration Program, and a Longevity Program. Together, OmniTAC serves as the core platform and the disease-area programs are the product outputs it produces for internal advancement and partnered development.
Differentiator
Problem solved
Functional benefit
Brands
- OmniTAC™: General Proximity's proprietary induced proximity medicines discovery platform. OmniTAC™ enables unbiased identification of effector proteins capable of modulating disease-relevant targets.
Products and services
- OmniTAC™ Platform Proprietary mechanism-agnostic proximity discovery engine that performs unbiased scanning of the effectome (the set of all effector proteins capable of modulating other proteins — chaperones, adaptors, trafficking proteins, PTM readers/writers/erasers) to discover the most powerful proximity mechanism for any given disease target, enabling the design of heterobifunctional induced-proximity medicines for previously undruggable targets.
- OmniTAC™ Oncology Programs Oncology-focused preclinical programs generated by the OmniTAC™ platform, including a multi-target collaboration with Daiichi Sankyo to identify novel effector–target pairs and develop first-in-class candidates for high-value oncology targets, plus an ARPA-H-funded women's cancer program (Triple Negative Breast Cancer and broader women's cancer space).
- Cardiometabolic Disease Program Preclinical pipeline program leveraging the OmniTAC™ platform to address undruggable protein targets implicated in cardiometabolic disease.
- Neurodegeneration Program Preclinical pipeline program leveraging the OmniTAC™ platform to address undruggable protein targets associated with neurodegenerative diseases, including dementia-related targets.
- Longevity Program Preclinical pipeline program applying the OmniTAC™ platform to address undruggable protein targets relevant to human healthspan and longevity.
Companies that use General Proximity
Customer profileNamed customers2 records
Segments5 records
Ideal customer profiles3 records
General Proximity technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature6 records
General Proximity partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship / core, core and minor.
- Daiichi Sankyoflagship / coreMulti-target strategic collaboration through Daiichi Sankyo Research Institute in Boston to apply GP's OmniTAC™ platform to oncology programs of interest to Daiichi Sankyo. GP will leverage OmniTAC™ to discover and characterize novel effector-target pairs with the potential to generate first-in-class therapeutic candidates for high-value oncology targets. Announced November 12, 2025.
- Amazon Web Services (AWS)coreAWS provides HealthOmics and high-performance computing infrastructure plus AWS credits funded by AWS Social Responsibility & Impact and technical support, facilitated through the ARPA-H Investor Catalyst Hub, to accelerate GP's cancer research. Announced June 10, 2025 as part of expanded AWS support for ARPA-H Sprint performers.
- Johnson & Johnson Innovation – JLABScoreGP won a coveted spot in Johnson & Johnson's JLABS biotech incubator, which provides access to lab space and mentorship. Listed as a collaborating institution on GP's homepage.
- UCSF (University of California, San Francisco)minorListed on GP's homepage as a world-class collaborating institution. Several team members (including Armand Cognetta's scientific lineage and current employees) come from UCSF.
- Moffitt Cancer CenterminorListed on GP's homepage as a world-class collaborating institution.
- MBC BiolabscoreMBC Biolabs provides lab space and operational support for General Proximity (listed under 'Supported by major grants' on homepage). MBC Biolabs is a San Francisco biotech incubator.
Scale indicators16 records
Recent moves6 records
Expansion highlights6 records
General Proximity competitors and assessment
Company assessmentDirect peers
- Arvinas: Clinical-stage pioneer of PROTAC-induced-proximity medicines targeting undruggable proteins. Most direct comparable in the proximity-medicine modality; GP's SAB includes Arvinas's former CTO Andy Crew, and Arvinas represents the benchmark GP must differentiate against.
- Photys Therapeutics: Developer of PHICS (phosphorylation-inducing heterobifunctional small molecules) — a next-generation induced-proximity modality. GP scientist Veronika Shoba co-founded PHICS at the Broad Institute (Choudhary lab), making Photys a closely comparable modality peer.
- Lyterian Therapeutics: Early-stage induced-proximity company developing bifunctional degraders and broader proximity therapeutics. GP scientist Minh Tran previously worked at Lyterian, making it a directly comparable preclinical proximity platform.
- C4 Therapeutics: Clinical-stage developer of targeted protein degraders (Degronimids) using induced proximity. Publicly traded (CCCC) with active pharma collaborations; represents a more advanced and capitalized proximity-medicine peer.
- Kymera Therapeutics: Clinical-stage immunology- and oncology-focused targeted protein degradation company (KT-474, KT-621). Publicly traded (KYMR) with major pharma partnerships (Sanofi) — a more advanced induced-proximity peer.
- Monte Rosa Therapeutics: Clinical-stage developer of molecular glue degraders (e.g., MRTX1719 for PRMT5). Publicly traded (GLUE) and a key competitor in mechanism-induced proximity against previously undruggable cancer targets.
- Vividion Therapeutics: Chemoproteomics-based drug discovery platform that develops covalent and proximity-inducing drugs. Acquired by Bayer for $1.5B in 2021; GP founder Armand Cognetta co-authored foundational IP underlying Vividion while in the Cravatt lab at Scripps.
Emerging players
- Foghorn Therapeutics: Clinical-stage chromatin-biology platform company developing selective small molecules against previously undruggable chromatin regulatory targets. Comparable as a platform approaching undruggable targets with novel modalities.
- Santa Ana Bio: Early-stage immunology biotech with experienced BD leadership (former Caribou CBO, where GP CBO Timothy Herpin also served). Comparable as an early-stage biotech leveraging experienced pharma BD leadership for enterprise partnerships.
Broad incumbents
- Schrödinger: Computational drug discovery platform with active pipeline and pharma collaborations. Dr. Margaret Dugan (GP SAB member) is CMO at Schrödinger; comparable as a physics/computation-driven discovery platform serving pharma partners.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
General Proximity social profiles
Digital presenceGeneral Proximity financial estimates
Financial estimateRevenue estimate
Valuation estimate
General Proximity leadership team
Management profileNumber of profiles
Profiles9 records
General Proximity subsidiaries and ownership
Company hierarchySubsidiaries1 record
General Proximity funding detail
Funding detailFunding overview
Funding rounds2 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
General Proximity M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about General Proximity
What does General Proximity do?
General Proximity develops the proprietary OmniTAC™ platform, a mechanism-agnostic proximity discovery engine that scans the "effectome" to identify effector proteins capable of modulating disease-driving targets. The platform generates preclinical induced-proximity therapeutic candidates (heterobifunctional/bifunctional small molecules) against previously undruggable targets across oncology, cardiometabolic disease, neurodegeneration, and longevity, delivered to large-pharma partners via multi-target discovery collaborations and licensing deals.
Is General Proximity a public or private company?
General Proximity is a private company. It is classified as venture growth investor backed and is currently operating.
When was General Proximity founded?
General Proximity was founded in 2019. It employs 11 to 50 people.
Where is General Proximity based?
General Proximity is headquartered in San Francisco, United States, in the North America region.
How does General Proximity make money?
Four revenue lines are on record. Pharma discovery & collaboration agreements are the primary driver. The others are strategic equity investment from pharma/VC partners, non-dilutive grant funding and venture capital / private equity financing.
Who are General Proximity's main competitors?
Direct peers on record are Arvinas, Photys Therapeutics, Lyterian Therapeutics, C4 Therapeutics, Kymera Therapeutics, Monte Rosa Therapeutics and Vividion Therapeutics. Emerging players are Foghorn Therapeutics and Santa Ana Bio. Schrödinger is listed as a broad incumbent.
Does General Proximity have an API?
No public API is recorded for General Proximity.
What industry is General Proximity in?
General Proximity's product category is Biotechnology Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.